AgingResearch.NewsJoin free

Character Bio

Company

Character Bio develops 2 assets, the furthest in phase 1 (CTX114 in geographic atrophy).

2
Assets
Furthest stage
Phase 1
Raised
$93M
0
Trials
1
Signal

Pipeline

2

  • CTX114

    Inhibits complement attack at the retinal surface to protect retinal and photoreceptor cells.

    Phase 1, geographic atrophy

  • CTX203

    Restores lipid homeostasis to prevent progression to advanced disease.

    Phase 1, high risk intermediate AMD

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Funding rounds and grants1
  • People14
  • Signals1
  • Similar companies6

Papers

Intelligence